SOURCE: Hard to Treat Diseases Inc.

August 23, 2007 08:00 ET

Hard To Treat Diseases, Incorporated Announces: Status of Tubercin and the Company

DELRAY BEACH, FL--(Marketwire - August 23, 2007) - Hard To Treat Diseases, Incorporated (HTTD) (PINKSHEETS: HTDS) announces the following information in response to recent inquiries regarding Tubercin and the status of HTTD.

HTTD sold its drug-related intellectual property rights to Cavit Sciences, Inc. ("CVIT") on May 31, 2006. The rights sold include patent application rights for numerous indications of Tubercin.

On May 1, 2006, Dr. Tai-Ho Chung and Mr. Chong-Chan Chung ("Chungs") formally terminated their Tubercin License Agreement with Shinn Capital Group, Inc.

On November 30, 2006, the Chungs assigned the rights and interest in their Tubercin patent to a private Korean company, Hyolim Bio Co., Ltd. The Chungs are actively involved with Hyolim Bio Co., Ltd.

In February 2007, the Chungs notified the Securities and Exchange Commission ("SEC") that their license agreement with Shinn Capital Group, Inc. had been terminated and that Hyolim Bio Co., Ltd. and the Chungs have no association in any manner with Ronald Shinn, Shinn Capital Group, Inc. or ArTec Inc. ("ATKJ") and its website claims.

HTTD has a judgment against Ronald Shinn of approximately $210,000 based on the U.S. Court of Appeals ruling that Shinn is personally liable for breach of fiduciary duty to HTTD for damages on the basis of his misappropriation of corporate funds from HTTD.

HTTD has supplied all supporting documentation to the SEC regarding the securities fraud and other fraudulent activities committed by the prior officers and directors of the Company.

Additional information is available on the Company's website at: Contact the Company or the SEC if you have any questions.

Cautionary Note Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard To Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Contact Information